Investors Purchase Large Volume of Call Options on Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of some unusual options trading on Tuesday. Traders bought 186,301 call options on the stock. This is an increase of approximately 26% compared to the average daily volume of 147,317 call options.

Insider Buying and Selling

In related news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the sale, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 82,963 shares of company stock worth $2,944,621. 17.71% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HIMS. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health during the second quarter valued at $26,000. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter worth about $28,000. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health during the 3rd quarter valued at about $28,000. Finally, Quaker Wealth Management LLC bought a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $29,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Down 0.5%

NYSE HIMS opened at $15.43 on Wednesday. The stock’s 50 day simple moving average is $27.79 and its 200 day simple moving average is $39.76. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43. The firm has a market cap of $3.51 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 2.90 and a beta of 2.43. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The business’s revenue was up 28.4% on a year-over-year basis. As a group, sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HIMS shares. TD Cowen decreased their target price on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research report on Tuesday. Morgan Stanley set a $21.00 price target on shares of Hims & Hers Health in a research note on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Bank of America cut their target price on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, February 9th. Finally, Citigroup decreased their price target on Hims & Hers Health from $16.50 to $13.25 and set a “sell” rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Reduce” and a consensus target price of $32.27.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.